Ex-Head of Galderma Xavier Yon joins Board of Michelson Diagnostics

Ex-Galderma CEO Xavier Yon has joined the board of UK-based skin cancer scanner firm Michelson Diagnostics Ltd as non-executive Director.

Xavier has spent more than 40 years in the medical industry, of which 15 years was spent as CEO of the major dermatology company Galderma. Under his leadership Galderma grew worldwide sales to $800 million; today Galderma employs more than 4,000 people in over 30 countries and has a turnover in excess of $1.4BN.

Prior to joining Galderma Xavier’s career included senior positions with Pfizer, Solvay and Alcon.

He holds board positions with a number of dermatology industry businesses including non-invasive skin cancer treatment company Photocure, skin regeneration specialist Elastagen and also the veterinary technology supplier Virbac Animal Health.

Xavier says: “Since my tenure with Galderma, I have always been attracted by new technologies in the field of dermatology, those which offer real value addition to the practitioners and their patients. VivoSight is definitely a unique device that falls into that category of breakthrough technology. Together with the Michelson Diagnostics Team, I intend to help making VivoSight available to clinicians in selected EU countries and in the US”

Michelson Diagnostics Ltd markets the VivoSight® OCT scanner, which provides detailed real-time images of sub-surface skin tissue. Being able to see beneath the skin surface is very helpful to dermatologists. Scanning is quick, safe, requires no special preparation and there are no side-effects.

The VivoSight® OCT scanner is being used at leading clinics in Germany on a routine basis, to aid the detection, selection of treatment and monitoring of non-melanoma skin cancers.

Xavier’s appointment comes at an exciting time in Michelson Diagnostics’ growth as a leading player in skin imaging. Brian Howlett, Chairman of Michelson Diagnostics, said: “I am delighted that Xavier has joined the team. He brings with him great experience of the clinical dermatology market, and a valuable network of industry contacts, and will be able to support the management team grow sales in current and future markets and to develop strategic relationships for accelerating growth.”

Media Enquiries

e: media@vivosight.com

t: +44 (0)20 8308 1695